Underwhelming data detract from perampanel's innovative mechanism in epilepsy
This article was originally published in Scrip
Eisai signalled that it will remain a player in the epilepsy field following the unveiling of positive data from the latest Phase III clinical trial of its novel anti-epileptic drug perampanel at the 29th International Epilepsy Congress in Rome. Dr Jacqueline French, Director of the Clinical Trials Consortium at New York University’s Epilepsy Center, presented new clinical trial data from perampanel's third and final Phase III clinical trial (Study 305) of its EXPLORE (Examining Perampanel Observations from Research Experience) clinical trial programme.
You may also be interested in...
Perampanel has become the first AMPA receptor antagonist to gain approval for the adjunctive treatment of partial-onset seizures. Despite underwhelming clinical trial data and relatively late market entry, perampanel's novel class, convenient dosing regimen, and preferable side-effect profile will support its uptake in the refractory patient population.
Safety concerns and high price points have previously limited use of Novartis’s Gilenya (fingolimod) in the European multiple sclerosis market since its launch in January 2011. However, the decision by the UK's NICE to recommend Gilenya for active relapsing-remitting multiple sclerosis will support the product's future sales which are estimated to reach $2.2 billion across the seven major markets by 2020.
The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.